XenoPort to Release Third Quarter Financial Results on October 24, 2012

Before you go, we thought you'd like these...
Before you go close icon

XenoPort to Release Third Quarter Financial Results on October 24, 2012

SANTA CLARA, Calif.--(BUSINESS WIRE)-- XenoPort, Inc. (NAS: XNPT) announced today that it will release its third quarter financial results on October 24, 2012 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event.

To access the conference call via the Internet, go to www.XenoPort.com. Please join the call at least 15 minutes prior to the start to ensure time for any software downloads that may be required.


To access the live conference call via phone, dial 1-888-275-3514. International callers may access the live call by dialing 706-679-1417. The reference number to enter the call is 51875216.

The replay of the conference call may be accessed that same day after 8:00 p.m. Eastern Time, via the Internet, at www.XenoPort.com, or via phone at 1-800-642-1687 for domestic callers, or 706-645-9291 for international callers. The reference number to enter the replay of the call is 51875216.

About XenoPort

XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved in the United States for the treatment of moderate-to-severe primary restless legs syndrome (RLS) in adults and for the management of postherpetic neuralgia in adults. GlaxoSmithKline holds commercialization rights and certain development rights for Horizant in the United States. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved for the treatment of RLS in Japan. Astellas Pharma Inc. holds all development and commercialization rights for Regnite in Japan and five other Asian countries. XenoPort holds all other world-wide rights and has co-promotion and certain development rights to gabapentin enacarbil in the United States. XenoPort's pipeline of product candidates includes potential treatments for patients with spasticity, Parkinson's disease and relapsing-remitting multiple sclerosis.

To learn more about XenoPort, please visit the company Website at www.XenoPort.com.

XENOPORT and Regnite are registered trademarks of XenoPort, Inc.
Horizant is a registered trademark of GlaxoSmithKline.

XNPT2F



XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:

The article XenoPort to Release Third Quarter Financial Results on October 24, 2012 originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners